ERCC1在Ⅱ期结直肠癌中的表达及其临床意义

Expression and its clinical significance of ERCC1 in stage Ⅱ colorectal carcinoma

目的探讨核苷酸切除修复交叉互补基因1(ERCC1)在Ⅱ期结直肠癌中的表达及其临床意义。方法采用免疫荧光技术检测56例Ⅱ期结直肠癌术后癌组织中ERCC1的表达,SPSS 13.0统计软件进行数据分析。结果癌组织中ERCC1表达低于正常肠黏膜组织(P=0.01),复发或转移患者ERCC1表达低于未出现患者(P=0.002),T3患者ERCC1表达高于T4患者(P=0.044),差异均有统计学意义。ERCC1表达与总生存率和无病生存率均呈正相关(P=0.000;P=0.000)。ERCC1高表达组中,接受含奥沙利铂方案辅助化疗患者和未接受化疗的患者5年总生存率和无病生存率差异均无统计学意义(P=0.351;P=0.465);ERCC1低表达组中,接受含奥沙利铂方案辅助化疗患者5年总生存率和无病生存率均高于未接受化疗的患者,差异均有统计学意义(P=0.015;P=0.02)。ERCC1(P=0.031)和复发转移(P=0.009)是影响总生存率的独立预后因素,复发转移(P=0.000)是影响无病生存率的独立预后因素。结论 ERCC1是影响Ⅱ期结直肠癌患者总生存率的独立预后因素;ERCC1低表达患者预后差,但可从含奥沙利铂方案的辅助化疗中获益。

Objective To investigate the expression and clinical significance of excision repair cross complementing gene 1（ERCC1）in colorectal carcinoma of stage Ⅱ and its clinical significance.Methods We collected 56 cases of stage Ⅱ postoperative colorectal carcinoma tissue and detected ERCC1 expression with immunofluorescence technique.Statistical analysis was made with SPSS13.0 software.Results ERCC1 expression was obviously lower in stage Ⅱ postoperative colorectal carcinoma tissue than in normal tissue（P=0.01）.In cancer tissue,ERCC1 expression in patients with relapse or metastasis was significantly lower than in those without（P=0.002）;ERCC1 expression in patients with T_3 was significantly higher than those with T_4（P=0.044）.ERCC1 expression had a positive correlation with the overall survival（OS）and disease-free survival（DFS）（both P=0.000）.In the group of high ERCC1 expression patients,five-year OS rate and DFS rate between patients who had received oxaliplatin-based adjuvant chemotherapy and those who did not have no significant difference（P=0.351;P=0.465）.In the group of low ERCC1 expression patients,five-year OS rate and DFS rate of patients who received oxaliplatin-based adjuvant chemotherapy were significantly higher than those of patients who did not（P=0.015,P=0.02）.ERCC1（P=0.031）and relapse or metastasis（P=0.009）were independent factors affecting OS;relapse or metastasis（P=0.000）was an independent factor affecting DFS.Conclusion ERCC1 is an independent factor affecting the OS of patients with stage Ⅱ colorectal carcinoma.Patients with low ERCC1 expression have poor prognosis,but they can benefit from oxaliplatin-based adjuvant chemotherapy.